Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis
2024-518859-27-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozanimod in multiple sclerosis (MS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: CSF and serum CXCL13 concentration change. Planned start Nov 2024; status: authorised.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-518859-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518859-27-00.